Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Basware Corporation - Managers' Transactions: Tykkyläinen, Vesa

Basware Corporation, stock exchange release, November 4, 2016 at 10:30Basware Corporation - Managers' Transactions: Tykkyläinen, VesaPerson subject to the notification requirementName: Tykkyläinen, VesaPosition: Chief Executive OfficerIssuer: Basware OyjLEI: 743700ULKFAAEA2N3D13Notification type: INITIAL NOTIFICATIONReference number: 743700ULKFAAEA2N3D13_20161103143636_2____________________________________________ Transaction date: 2016-11-02Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009008403Nature of the transaction: ACQUISITION(X)

Agreement with Production Partner for HAMLET Peptide

Hamlet Pharma reaches the important goal of establishing large-scale production of the drug candidate for Phase II clinical trials. For this purpose, Hamlet Pharma now signs a production and development agreement with PolyPeptide Laboratories Holding (PPL) AB. PPL is part of the PolyPeptide Group - one of the largest contract manufacturers of peptides and peptide-related molecules in the world. PolyPeptide is represented globally with manufacturing facilities in the US, Europe and India that have been approved by the FDA. The implementation of Phase II clinical studies requires large

European Patent Office grants patents for VAL001

European Patent Office (EPO) has announced the intent to grant Respiratorius patent for VAL001, "A Pharmaceutical Composition Comprising a HDAC inhibitor and a steroid and the use thereof."The patent applies to a combination of a HDAC inhibitor and a steroid for pretreatment before chemotherapy (R-CHOP) in the treatment of diffuse large B-cell lymphoma (DLBCL), a lymphoma which annually affects about 60,000 people in the United States and Europe. DLBCL is the most common type of Non-Hodgkin's lymphoma, which comprises 30% of diagnosed patients in the EU. After the formal fees are paid,

Viking Line to donate part of its cruise revenue to Red Nose Day

A cruise does people good. Viking Line is taking part in the 2016 Red Nose Day charity event and will donate one euro for every passenger who books a sailing through the Red Nose Day campaign, which runs November 4–14, 2016. The money raised will help give some of the world’s most vulnerable children better access to education, health care, security and nutrition.Red Nose Day has been held in Finland since 2007 in order to raise funds to help children around the world. YLE Helps, the non-profit organization behind Red Nose Day in Finland, serves as a campaign agency for nine partners –

MOBERG PHARMA’S NOMINATION COMMITTEE APPOINTED

STOCKHOLM, November 4th, 2016 - In accordance with the resolution of the Annual General Meeting on May 18, 2016, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of

Nuevolution appoints Redeye as Certified Adviser

Stockholm, 4 November 2016. Nuevolution AB (publ) (NUE.ST) announced today that it has signed an agreement with and appointed Redeye AB as Certified Adviser as per 1 December 2016.  For more information, please contact: Alex Haahr Gouliaev Chief Executive Officer Phone: +45 7020 0987 Email: ahg@nuevolution.com  Henrik D. Simonsen Chief Financial Officer Phone: +45 3913 0947 Email: hs@nuevolution.com  About Nuevolution Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark.

Volvo Group intends to initiate a process to divest Governmental Sales

Volvo Group intends to initiate a process in order to divest its Governmental Sales business area.Volvo Group has conducted a strategic review of the Governmental Sales business area and intends to initiate a process to divest this business. “Governmental Sales has built a very strong position over the last few years with a positive development and a record order book. There are great opportunities to grow the business even further, however, we believe that a new owner may be better placed to take the business to the next level. Consequently, we intend to start preparations to divest the

Interim report 1 July – 30 September, 2016

Third quarter compared to 2015, Group » Group net sales increased by 244% to SEK 516,641 (150,174). » Other operating income amounted to SEK 91,495 (1 212 350) and is related to capitalized development costs. » Loss for the period amounted to SEK -15,042,517 (-10,908,522). » Earnings per share (weighted average) amounted to SEK -0.94 (-0.92).   First nine months 2016, compared to first nine months 2015, Group » Group net sales increased by 118% to SEK 1,397,855 (641,094). » Other operating income amounted to SEK 1,038,529 (3,778,750) and is related to capitalized

Revenio Group Corporation: Managers' transactions

Revenio Group Corporation, Stock Exchange Release, November 4, 2016 at 9.15Managers' transactionsPerson subject to the notification requirementName: Salovaara Olli-Pekka Legal PersonPosition: Chief Executive Officer Initial Notification IssuerName: Revenio Group Oyj Transaction detailsTransaction date: 31-10-2016Nature of the transaction: Gift, Donation or Inheritance (Received) Instrument: ShareISIN: FI0009010912 Volume:

Ratos AB: Arcus prepares for IPO

4 November 2016 Ratos and its subsidiary Arcus (formerly ArcusGruppen), one of the leading wine and spirits suppliers in the Nordic region, intend to list the company's shares on the Oslo Stock Exchange. A listing of Arcus is expected to deliver a strong and diversified long-term ownership base that can support the company's continued growth strategy and strengthen its market position.In 2005, when Ratos acquired Arcus, the company was predominantly a Norwegian spirits producer, which has developed under Ratos's majority ownership into the Nordic region's leading supplier of wines and

Obducat receives order from Leibniz-Institute of Surface Modification (IOM) in Leipzig.

OBDUCAT AB (publ) subsidiary solar-semi GmbH, a leading supplier of system solutions for lithography processing, has received an order from IOM, Leipzig in Germany, for the supply of a Quickstep QS W 300 SM Mask Cleaner system. The order value amounts to approx. 1.8 MSEK.The Quickstep system will be installed in the cleanroom facilities of the Physical Department at IOM in Leipzig. IOM conducts interdisciplinary, application-oriented basic research focusing on topics related to the interaction of radiation with matter. The core competencies of the IOM are the modification and development of

Etteplan develops virtual showroom for KONE

Etteplan has developed a virtual showroom for KONE Marine, which KONE will use to present its People Flow solutions for passenger ships to its customers.In the Virtual Reality (VR) environment designed by Etteplan, customers wear HMD glasses to familiarize themselves with elevators and call panels in a ship’s lobby, giving them the impression of actually being on a completed ship. The virtual world allows customers to perceive the functionality of the space and elevator solutions, and the material and product components used in the products, better than through traditional methods. For KONE,

Successful closing of the Transaction

Oslo, 4 November 2016Reference is made to the stock exchange announcements made on 31 October 2016 regarding CFIUS approval and Transaction closing. Opera Software ASA (“Opera” or the “Company”) is pleased to announce that the transaction between Opera Software ASA and Golden Brick Capital Private Equity Fund I L.P. (the “Buyer”) on the sale and purchase of Opera's consumer business for $575 million (the “Transaction”) has been successfully closed.  “This has been a long process, but we strongly believe the Transaction provides a great outcome for the consumer business and the

Improved operating margin and organic growth

July – September 2016Revenue for the third quarter amounted to SEK 4,200 million (4,167). Organic growth was 3 percent (3) and real growth was 2 percent (4).Loomis operating income (EBITA)[1] amounted to SEK 528 million (483) and the operating margin was 12.6 percent (11.6).Income before taxes amounted to SEK 533 million (445) and income after taxes was SEK 391 million (329).Earnings per share before and after dilution amounted to SEK 5.20 (4.37).Cash flow from operating activities amounted to SEK 536 million (379), equivalent to 102 percent (78) of operating income (EBITA).

INDEPENDENT STATEMENT ON MANDATORY OFFER

In connection with the mandatory offer by Zono Holding AS to acquire the remaining shares of Techstep ASA, Arctic Securities has performed an independent valuation of the offer in accordance with Section 6-16 of the Securities Trading Act. The full text of the statement issued by Arctic Securities is provided as an attachment (link) in this announcement. techstep-arctic-independent-statement  This information is subject to disclosure requirements pursuant to Section 5-12 of the Norwegian

Resolutions to increase the share capital in Targovax ASA in relation to exercise of employee options and settlement of restricted stock units

The board of directors of Targovax ASA (the "Company") has on 3 November 2016, in accordance with the authorisations granted by the general meeting 13 April 2016, resolved: · to increase the share capital of up to NOK 114,542.90 by issuance of up to 1,145,429 new shares, each with a nominal value of NOK 0.10 in order to facilitate the exercise of vested employee options; and  · to increase the share capital of up to NOK 6,987.90 by issuance of up to 69,879 new shares, each with a nominal value of NOK 0.10 in order to facilitate the settlement of vested restricted stock units ("

Catella AB – Interim Report January-September 2016

Catella’s total income increased by 5% in the third quarter, mainly attributable to the Banking business area. Income was up despite lower performance-based earnings, amounting to SEK 477 M (455). The fixed earnings were up as a result of increased assets under management, improving earnings stability and generating potential for increased performance-based earnings looking ahead.Third quarter The Group · Total income SEK 477 M (455) · Net sales SEK 475 M (455) · Operating profit/loss SEK 51 M (55) · Operating profit/loss SEK 50 M (53) · Profit/loss before tax SEK 56 M (

Safety Review Committee for Nordic Nanovector’s Lymrit 37-01 trial recommends dose escalation to 20 MBq/kg with Betalutin®

Oslo, Norway, 4 November 2016 Nordic Nanovector ASA (OSE: NANO) announces that the independent Safety Review Committee (SRC) for the ongoing Lymrit 37-01 clinical trial of Betalutin® in relapsed/refractory NHL, has recommended escalating the dose of Betalutin® in Arm 4 from 15 MBq/kg to 20 MBq/kg following pre-dosing with 100 mg/m2 lilotomab. Recruitment of 3 patients into Arm 4 to receive this new higher dosing regimen is now underway. The SRC also concluded that Arm 3 should be discontinued. The decision follows a review by the SRC of the available safety and dosimetry data from the

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Valby, Denmark, 3 November 2016 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.1. Details of the person discharging managerial responsibilities / person closely associateda) Name Lars Bang2. Reason for the notificationa) Position/status Executive Vice President, Supply Operations & Engineeringb) Initial Initial notification notification/

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic Series to China

Free youth baseball clinic to feature Billy Brewer and Todd HaneyColorado Springs, Colo. – Chinese youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series. The MLBPAA’s first trip to China since the Legends for Youth baseball clinic series’ induction will feature MLB veterans Billy Brewer and Todd Haney. Brewer’s career spanned seven seasons, pitching for the Royals, Yankees, Athletics and Phillies and led the majors in 1993 by allowing only 10.3% of inherited runners to

Invitation to DNB's Capital Markets Day – 16 November 2016

DNB is pleased to invite you to the Group’s Capital Markets Day. Date: Wednesday 16 November 2016Time: 12:30 pm – 3:30 pmLocation: Hotel Claridge's, Brook Street, Mayfair, London W1K 4HR, England Registration and lunch from 11:30 am – 12:30 pmWe will present the most important challenges and opportunities facing DNB in today’s rapidly changing business environment. Topics will include the Group’s operating environment, digitalisation, ROE, asset quality and capital. RegistrationPlease register your attendance with Wendy.Busuttil@dnb.no (Wendy.Busuttil@dnb.no?

London Universities Purchasing Consortium selects Corps Security

Corps Security, the leading provider of specialist security services, has announced that it has been awarded a place on the prestigious London Universities Purchasing Consortium (LUPC) framework agreement for Security Services. Under this new agreement the company will supply a range of services from its portfolio to a broad range of universities and colleges of higher education in and around the capital and the South East of England, as well as other not-for-profit organisations in the arts and culture sectors. LUPC was established in 1968 as a not-for-profit professional buying

AKTIA BANK PLC: SHARE REPURCHASE 03.11.2016

AKTIA BANK PLC: SHARE REPURCHASE 03.11.2016                                                            Helsinki Stock Exchange                                                      Trade date                                         03.11.2016                        Bourse trade                                      PURCHASEAmount                                             2700 shares Total cost                                          24 419,00 EUR           Average price / share                       9,044074  EUR           Highest price / share                         9,10

There are no items matching the current filter
There are no more items matching the current filter
Back to top